Antoxis is developing treatments for various neurological conditions.
Antoxis is a pre-clinical drug discovery company that utilises its patented Kromex™ chemistry scaffold to generate New Chemical Entities (NCE) targeting a number of high-value clinical indications.This innovative Kromex™ scaffold is developed from an in-depth knowledge of free radical biology and redox chemistry and protects over 100 Million compounds. This Kromex™ NCE library contains molecules with potential to modulate a broad spectrum of oxidative stress associated diseases and conditions that involve mitochondrial dysfunction. Antoxis is currently focusing its efforts on a sub-set of Kromex™ compounds that show rapid mito-targeting (minutes), potent mito-activity (100 fold greater than competing agents) and long term stability within the cell (48 h). With patent grants in a number of key territories including the US, Antoxis lead compounds can be separated into two potent drug families:(i) Oxidative stress inhibitors associated with mitochondrial dysfunctionProxison™ - a powerful co-treatment that maximizes the clinical outcomes of regenerative medicine therapies (cell quality and cell numbers). Proxison™ compounds are also being developed for the treatment of neurodegenerative diseases(ii) Mitochondrial redox modulators for the (co-therapy) treatment of drug-resistant cancerOncamex™ shows drug synergy with a number of cancer therapies and when used in combination can reverse cell line resistance to treatments
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 16, 2009 | Seed | £300K | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Grampian Biopartners | — | Seed |